dc.date.accessioned | 2020-12-10T18:56:34Z | |
dc.date.available | 2020-12-10T18:56:34Z | |
dc.date.created | 2020-12-03T12:05:12Z | |
dc.date.issued | 2020 | |
dc.identifier.citation | Vetyskova, Veronika Zouharova, Monika Bednarova, Lucie Vaněk, Ondřej Sázelová, Petra Kašička, Václav Vymetal, Jiri Srp, Jaroslav Rumlová, Michaela Charnavets, Tatsiana Postulkova, Klara Reseland, Janne Elin Bousova, Kristyna Vondrasek, Jiri . Characterization of AMBN I and II isoforms and study of their Ca2+ binding properties. International Journal of Molecular Sciences. 2020, 21, 9293 | |
dc.identifier.uri | http://hdl.handle.net/10852/81567 | |
dc.description.abstract | Ameloblastin (Ambn) as an intrinsically disordered protein (IDP) stands for an important role in the formation of enamel—the hardest biomineralized tissue commonly formed in vertebrates. The human ameloblastin (AMBN) is expressed in two isoforms: full-length isoform I (AMBN ISO I) and isoform II (AMBN ISO II), which is about 15 amino acid residues shorter than AMBN ISO I. The significant feature of AMBN—its oligomerization ability—is enabled due to a specific sequence encoded by exon 5 present at the N-terminal part in both known isoforms. In this study, we characterized AMBN ISO I and AMBN ISO II by biochemical and biophysical methods to determine their common features and differences. We confirmed that both AMBN ISO I and AMBN ISO II form oligomers in in vitro conditions. Due to an important role of AMBN in biomineralization, we further addressed the calcium (Ca2+)-binding properties of AMBN ISO I and ISO II. The binding properties of AMBN to Ca2+ may explain the role of AMBN in biomineralization and more generally in Ca2+ homeostasis processes. | |
dc.language | EN | |
dc.rights | Attribution 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.title | Characterization of AMBN I and II isoforms and study of their Ca2+ binding properties | |
dc.type | Journal article | |
dc.creator.author | Vetyskova, Veronika | |
dc.creator.author | Zouharova, Monika | |
dc.creator.author | Bednarova, Lucie | |
dc.creator.author | Vaněk, Ondřej | |
dc.creator.author | Sázelová, Petra | |
dc.creator.author | Kašička, Václav | |
dc.creator.author | Vymetal, Jiri | |
dc.creator.author | Srp, Jaroslav | |
dc.creator.author | Rumlová, Michaela | |
dc.creator.author | Charnavets, Tatsiana | |
dc.creator.author | Postulkova, Klara | |
dc.creator.author | Reseland, Janne Elin | |
dc.creator.author | Bousova, Kristyna | |
dc.creator.author | Vondrasek, Jiri | |
cristin.unitcode | 185,16,17,7 | |
cristin.unitname | Klinisk forskningslaboratorium | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.cristin | 1855772 | |
dc.identifier.bibliographiccitation | info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=International Journal of Molecular Sciences&rft.volume=21&rft.spage=9293&rft.date=2020 | |
dc.identifier.jtitle | International Journal of Molecular Sciences | |
dc.identifier.volume | 21 | |
dc.identifier.issue | 23 | |
dc.identifier.doi | https://doi.org/10.3390/ijms21239293 | |
dc.identifier.urn | URN:NBN:no-84649 | |
dc.type.document | Tidsskriftartikkel | |
dc.type.peerreviewed | Peer reviewed | |
dc.source.issn | 1422-0067 | |
dc.identifier.fulltext | Fulltext https://www.duo.uio.no/bitstream/handle/10852/81567/1/ijms-21-09293-v2.pdf | |
dc.type.version | PublishedVersion | |
cristin.articleid | 9293 | |